E. I. du Pont de Nemours and Company
http://www.dupont.com/
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From E. I. du Pont de Nemours and Company
Keeping Track: US FDA Clears Another CAR-T And Another Novel ADHD Drug; Submissions Blossom
The latest news and highlights from the Pink Sheet’s US FDA Performance Tracker.
Keeping Track: Regeneron Wins US FDA OK For Evkeeza, New Libtayo Uses; G1 Cosela Cleared
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker
ADCs, Oncology Move To Fore In Korean Biopharma Alliances
Although there weren’t many large-scale partnerships as in previous years, Korean biopharma firms were involved in a broad range of deals across diverse therapeutic areas in 2020, with ADCs, oncology and domestic alliances emerging as key trends.
Asia Deal Watch: Astellas Acquires Global Rights To KaliVir Oncolytic Virus Candidate
Plus deals involving SELLAS/3D Medicines, Kyowa Kirin/InveniAI, JW/Voronoi, Y-mAbs/Takeda, Horizon Discovery/Sanyou, Sentinel Oncology/PharmaEngine
Company Information
- Industry
- Diversified
- Other Names / Subsidiaries
-
- DowDuPont
- DuPont